Sign inCreate account

Report workspace tools

NCT06722183RECRUITINGanonymous

FUTURE Platform Trial - A Phase II Platform Trial of Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

Sponsor

Source record

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase

Source record

PHASE2

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Futibatinib orally administered, Tislelizumab (i.v. 200mg)

Indication / condition

AI-normalized

Colorectal Cancer

Intervention

Source record

Futibatinib orally administered, Tislelizumab (i.v. 200mg)

Source & freshness

Source record

NCT ID

NCT06722183

Original source

ClinicalTrials.gov

Source last updated

Dec 24, 2025

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06722183

Title

FUTURE Platform Trial - A Phase II Platform Trial of Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Status

RECRUITING

Phase

PHASE2

Condition raw

Colorectal Cancer

Condition normalized

Colorectal Cancer

Modality raw

colorectal cancer

Modality normalized

monoclonal antibody

Target raw

Futibatinib orally administered, Tislelizumab (i.v. 200mg)

Target normalized

Futibatinib orally administered, Tislelizumab (i.v. 200mg)

Interventions

Futibatinib orally administered, Tislelizumab (i.v. 200mg)

Public preview

Source record

FUTURE Platform Trial - A Phase II Platform Trial of Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities is a PHASE2 clinical asset sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest in Colorectal Cancer. SEO and diligence focus: Futibatinib orally administered, Tislelizumab (i.v. 200mg), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

FUTURE Platform Trial - A Phase II Platform Trial of Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06722183

Status

RECRUITING

Phase

PHASE2

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Executive brief

Investment-Ready Snapshot

FUTURE Platform Trial - A Phase II Platform Trial of Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities is a PHASE2 clinical asset sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest in Colorectal Cancer. SEO and diligence focus: Futibatinib orally administered, Tislelizumab (i.v. 200mg), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedDec 24, 2025
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06722183

Indication

Colorectal Cancer

Modality

monoclonal antibody

Target

Futibatinib orally administered, Tislelizumab (i.v. 200mg)

Intervention

Futibatinib orally administered, Tislelizumab (i.v. 200mg)

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.